Correlation Between Veracyte and Sonnet Biotherapeutics

Can any of the company-specific risk be diversified away by investing in both Veracyte and Sonnet Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Veracyte and Sonnet Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Veracyte and Sonnet Biotherapeutics Holdings, you can compare the effects of market volatilities on Veracyte and Sonnet Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Veracyte with a short position of Sonnet Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Veracyte and Sonnet Biotherapeutics.

Diversification Opportunities for Veracyte and Sonnet Biotherapeutics

-0.57

Correlation Coefficient

Veracyte  Sonnet Biotherapeutics

Excellent diversification

The 3 months correlation between Veracyte and Sonnet is -0.57. Overlapping area represents the amount of risk that can be diversified away by holding Veracyte and Sonnet Biotherapeutics Holding in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Sonnet Biotherapeutics and Veracyte is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Veracyte are associated (or correlated) with Sonnet Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Sonnet Biotherapeutics has no effect on the direction of Veracyte i.e., Veracyte and Sonnet Biotherapeutics go up and down completely randomly.

Pair Corralation between Veracyte and Sonnet Biotherapeutics

Given the investment horizon of 90 days Veracyte is expected to generate 0.33 times more return on investment than Sonnet Biotherapeutics. However, Veracyte is 3.03 times less risky than Sonnet Biotherapeutics. It trades about 0.29 of its potential returns per unit of risk. Sonnet Biotherapeutics Holdings is currently generating about -0.24 per unit of risk. If you would invest  3,407  in Veracyte on August 16, 2024 and sell it today you would earn a total of  546.00  from holding Veracyte or generate 16.03% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Veracyte  vs.  Sonnet Biotherapeutics Holding

Veracyte

Risk-Adjusted Performance

10 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Veracyte are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Veracyte unveiled solid returns over the last few months and may actually be approaching a breakup point.

Sonnet Biotherapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Sonnet Biotherapeutics Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pair Trading with Veracyte and Sonnet Biotherapeutics

The main advantage of trading using opposite Veracyte and Sonnet Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Veracyte position performs unexpectedly, Sonnet Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sonnet Biotherapeutics will offset losses from the drop in Sonnet Biotherapeutics' long position.

The idea behind Veracyte and Sonnet Biotherapeutics Holdings pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.